Focal Salvage Brachytherapy Study (FocaSaBra) (FocaSaBra)
Prostate Cancer
About this trial
This is an interventional treatment trial for Prostate Cancer focused on measuring recurrence, prostate cancer, brachytherapy, focal treatment, salvage treatment, radiotherapy
Eligibility Criteria
Inclusion Criteria: Histopathologically confirmed by biopsy (fusion mapping biopsy preferred) recurrence of prostate cancer after prior radical radiotherapy (brachytherapy, external beam radiotherapy alone or with brachytherapy boost, stereotaxic radiotherapy) Localized tumor lesion assessed by MRI or in the case of MR contraindications with TRUS and CT Exclusion of distant metastases using CT, MR, or PET imaging PSA doubling time over six months PSA value <10 ng / ml No anti-androgen treatment in the year prior Dysuria on the IPSS (International Prostate Symptom Score) ≤ 20 points General condition according to the WHO scale ≤ 2 Signing informed consent to participate in the study Exclusion Criteria: PSA value> 10ng / ml General condition according to the WHO scale> 2 Dysuria on the IPSS scale> 20 points PSA doubling time <6 months Inability to discontinue anticoagulants. An active urinary tract infection. Contraindications to general anesthesia Active inflammatory bowel diseases. Second active cancer or treatment with completion less than 3 years earlier, except for low-stage skin cancer Estimated Survival <5 years
Sites / Locations
- Greater Poland Cancer Centre / Brachytherapy DepartmentRecruiting
Arms of the Study
Arm 1
Experimental
Experimental
Experimental: All recruited participants will be treated with salvage partial (focal) prostate brachytherapy for the lesion of recurrent prostate cancer with appropriate margin.